# Lorlatinib - PF-06463922

> **NCT03127618** · — · APPROVED_FOR_MARKETING · sponsor: **Pfizer**

## Conditions studied

_None listed._

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT03127618
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03127618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03127618, "Lorlatinib - PF-06463922". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03127618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*